Capricor Q1 2022 Earnings Report
Key Takeaways
Capricor Therapeutics reported a net loss of $7.8 million, or $0.32 per share, for the first quarter of 2022. The company's cash and cash equivalents totaled approximately $58.3 million as of March 31, 2022, bolstered by a $30 million upfront payment from Nippon Shinyaku for the commercialization and distribution of CAP-1002.
Secured partnership with Nippon Shinyaku for CAP-1002 commercialization in the US, receiving $30 million upfront.
Published positive Phase 2 results in The Lancet, validating CAP-1002's efficacy in treating DMD.
Advanced Phase 3 HOPE-3 trial preparations, with patient enrollment expected to begin in Q2 2022.
Expanded pipeline using engineered exosomes, investing in scaled-up manufacturing.
Capricor
Capricor
Forward Guidance
Capricor expects its available cash and cash equivalents will be sufficient to cover anticipated expenses and capital requirements for at least two years.